Jefferies lowered the firm’s price target on Astrana Health (ASTH) to $37 from $44 and keeps a Buy rating on the shares. The bar for fiscal 2026 EBITDA is low and implies little confidence in the full-risk contract conversion delays that management is assuming will be effective in the first quarter of 2026, the analyst tells investors in a research note. Jefferies believes potential upside for Astrana from Medicare Advantage in 2026 is underappreciated, but thinks proof-points on 1H26 trends are needed to restore confidence.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASTH:
- Astrana Health price target lowered to $26 from $36 at Barclays
- Astrana Health price target lowered to $35 from $40 at TD Cowen
- Astrana Health Inc. Reports Strong Q3 Earnings Amid Growth
- Astrana Health Reports Strong Revenue Growth in Q3 2025
- Strong Q3 Performance and Strategic Partnerships Justify Buy Rating for Astrana Health